The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

Hagop M. Kantarjian, Carlos E. Bueso-Ramos, Moshe Talpaz, Susan O'Brien, Francis Giles, Mary Beth Rios, Jianqin Shan, Jorge Cortes

Research output: Contribution to journalArticle

19 Scopus citations


One hundred and ten patients with Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) post-interferon-α failure treated with imatinib mesylate therapy were analyzed for the prognostic significance of marrow reticulin stain-measured fibrosis. The median time from diagnosis was 31 months. Severe reticulin (grade 3-4) fibrosis was observed in 67 patients (61%). Patients with severe marrow fibrosis had similar complete cytogenetic response rates with imatinib (67 vs. 58%; P=0.45) compared with those with mild-moderate fibrosis. The estimated 4 year survival rates (80 vs. 88%; P=0.27) and failure-free survival rates (69 vs. 77%; P=0.34) were also not different. We conclude that the previously established poor prognostic significance of marrow fibrosis in CML is less relevant with imatinib therapy.

Original languageEnglish (US)
Pages (from-to)993-997
Number of pages5
JournalLeukemia and Lymphoma
Issue number7
StatePublished - Jul 25 2005
Externally publishedYes



  • Chronic myelogenous leukemia (CML)
  • Imatinib mesylate
  • Marrow fibrosis
  • Philadelphia chromosome-positive chronic phase
  • Prognostic significance

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this